Terrific article by Kyle LaHucik on NG101?and its potential in reducing the nausea and vomiting associated with GLP-1s. Check it out.
Gastrointestinal side effects are one of the main concerns of the GLP-1 class. Neurogastrx, a GI biotech that had been testing a dopamine D2 antagonist for gastroparesis and has yet to share those Phase 2 results, has now emerged after a roughly three-year quiet period to unveil early data on pairing up its drug with Novo Nordisk's semaglutide. “The GLP-1s are miracle drugs,” Neurogastrx, Inc. CEO James O'Mara said in an interview with Endpoints News. But many patients stop taking the medicines within a year, and a lot of them cite the gastrointestinal side effects as a key reason, he said. More from my interview with O'Mara on NG101, the company's next steps, an update on the gastroparesis program and why the Boston-area biotech ended its Daewoong Pharmaceutical pact last year. #glp1 #obesity #weightloss #semaglutide #tirzepatide #wegovy #ozempic #zepbound #mounjaro #biotech #gastroparesis #nausea #vomiting #gibiotech